Background: Chronic hemodialysis requires a mode of vascular access through an arteriovenous fistula (AVF), a prosthetic arteriovenous graft (AVG), or a central venous catheter (CVC). AVF is recommended over AVG or CVC due to increased patency and decreased intervention rates for those that mature. AVG are preferred over CVC due to decreased infection and mortality risk. The aims of this study were to evaluate the lifespan of AVF and AVG in maturation, sustained access use, and abandonment. Methods: The United States Renal Data System (USRDS), Medicare claims, and CROWNWeb were used to identify access placements. Patients with a first end-stage renal disease (ESRD) service from January 1, 2012 to June 30, 2014 with continuous coverage with Medicare as primary payer and ≥1 AVF or AVG placed after ESRD onset were included. Maturation was defined as the first use of the access for hemodialysis recorded in CROWNWeb. Sustained access use was defined as 3 consecutive months of use without catheter placement or replacement. Accesses that were never used at any time post-placement were considered abandoned. Results: The cohort included 38,035 AVF placements and 12,789 AVG placements. Sixty-nine percent of AVF and 72% of AVG matured. Fifty-two percent of AVF and 51% of AVG achieved sustained access use. One quarter of AVF and 14% of AVG were abandoned without use as recorded in CROWNWeb. Conclusion: Although considered the gold standard for vascular access, only half of AVF and AVG placements achieved sustained access use. The USRDS database has inherent limitations but provides useful clinical insight into maturation, sustained use, and abandonment.

Keywords:
Vascular access, Hemodialysis, Maturation, Arteriovenous fistula, Arteriovenous graft
1.
United States Renal Data System: 2017 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2017, vol 2 – ESRD in the United States, pp 247–610.
2.
Vascular Access 2006 Work Group: Clinical practice guidelines for vascular access. Am J Kidney Dis 2006; 48(suppl 1):S176–S247.
3.
Malas MB, Canner JK, Hicks CW, Arhuidese IJ, Zarkowsky DS, Qazi U, Schneider EB, Black JH 3rd, Segev DL, Freischlag JA: Trends in incident hemodialysis access and mortality. JAMA Surg 2015; 150: 441–448.
4.
Lok CE, Foley R: Vascular access morbidity and mortality: trends of the last decade. Clin J Am Soc Nephrol 2013; 8: 1213–1219.
5.
Sidawy AN, Spergel LM, Besarab A, Allon M, Jennings WC, Padberg FT Jr, Murad MH, Montori VM, O’Hare AM, Calligaro KD, Macsata RA, Lumsden AB, Ascher E: The society for vascular surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. J Vasc Surg 2008; 48(5 suppl): 2s–25s.
6.
Allon M, Robbin ML: Increasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int 2002; 62: 1109–1124.
7.
Bylsma LC, Gage SM, Reichert H, Dahl SL, Lawson JH: Arteriovenous fistulae for haemodialysis: a systematic review and meta-analysis of efficacy and safety outcomes. Eur J Vasc Endovasc Surg 2017; 54: 513–522.
8.
Koirala N, Anvari E, McLennan G: Monitoring and surveillance of hemodialysis access. semin intervent radiol 2016; 33: 25–30.
9.
Donca IZ, Wish JB: Systemic barriers to optimal hemodialysis access. Semin nephrol 2012; 32: 519–529.
10.
Ethier J, Mendelssohn DC, Elder SJ, Hasegawa T, Akizawa T, Akiba T, Canaud BJ, Pisoni RL: Vascular access use and outcomes: an international perspective from the dialysis outcomes and practice patterns study. Nephrol Dial Transplant. 2008; 23: 3219–3226.
11.
Medicare Coverage of Kidney Dialysis & Kidney Transplant Services; in U.S. Department of Health and Human Services: Centers for Meidcare & Medicaid Services (ed). Baltimore, Centers for Medicare & Medicaid Services, 2017.
12.
The USRDS and its products. United states renal data system. Am J Kidney Dis. 1997; 30:S21–S39.
13.
StataCorp: Stata Statistical Software: Release 15. College Station, StataCorp LLC, 2017.
14.
Allon M, Imrey PB, Cheung AK, Radeva M, Alpers CE, Beck GJ, Dember LM, Farber A, Greene T, Himmelfarb J, Huber TS, Kaufman JS, Kusek JW, Roy-Chaudhury P, Robbin ML, Vazquez MA, Feldman HI: Relationships between clinical processes and arteriovenous fistula cannulation and maturation: a multicenter prospective cohort study. Am J Kidney Dis 2018; 71: 677–689.
15.
Dixon BS: Why don’t fistulas mature? Kidney Int 2006; 70: 1413–1422.
16.
Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M Jr, Miller A, Scher L, Trerotola S, Gregory RT, Rutherford RB, Kent KC: Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002; 35: 603–610.
17.
Shenoy S, Allon M, Beathard G, Brouwer-Maier D, Dember LM, Glickman M, Lee C, Litchfield T, Lok C, Huber T, Roy-Chaudhury P, Work J, West M, Wasse H: Clinical trial end points for hemodialysis vascular access: background, rationale, and definitions. Clin J Am Soc Nephrol 2018; 13: 490–494.
18.
Beathard GA, Lok CE, Glickman MH, Al-Jaishi AA, Bednarski D, Cull DL, Lawson JH, Lee TC, Niyyar VD, Syracuse D, Trerotola SO, Roy-Chaudhury P, Shenoy S, Underwood M, Wasse H, Woo K, Yuo TH, Huber TS: Definitions and end points for interventional studies for arteriovenous dialysis access. Clin J Am Soc Nephrol 2018; 13: 501–512.
19.
Woodside KJ, Bell S, Mukhopadhyay P, Repeck KJ, Robinson IT, Eckard AR, Dasmunshi S, Plattner BW, Pearson J, Schaubel DE, Pisoni RL, Saran R: Arteriovenous fistula maturation in prevalent hemodialysis patients in the United States: a National Study. Am J Kidney Dis 2018; 71: 793–801.
20.
Pisoni RL, Zepel L, Fluck R, Lok CE, Kawanishi H, Suleymanlar G, Wasse H, Tentori F, Zee J, Li Y, Schaubel D, Burke S, Robinson B: International differences in the location and use of arteriovenous accesses created for hemodialysis: results from the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2018; 71: 469–478.
21.
Glickman MH, Stokes GK, Ross JR, Schuman ED, Sternbergh WC 3rd, Lindberg JS, Money SM, Lorber MI: Multicenter evaluation of a polyurethaneurea vascular access graft as compared with the expanded polytetrafluoroethylene vascular access graft in hemodialysis applications. J Vasc Surg 2001; 34: 465–472; discussion 472–463.
22.
Glickman MH, Burgess J, Cull D, Roy-Chaudhury P, Schanzer H: Prospective multicenter study with a 1-year analysis of a new vascular graft used for early cannulation in patients undergoing hemodialysis. J Vasc Surg 2015; 62: 434–441.
23.
Xue H, Ix JH, Wang W, Brunelli SM, Lazarus M, Hakim R, Lacson E Jr: Hemodialysis access usage patterns in the incident dialysis year and associated catheter-related complications. Am J Kidney Dis 2013; 61: 123–130.
24.
Thamer M, Lee TC, Wasse H, Glickman MH, Qian J, Gottlieb D, Toner S, Pflederer TA: Medicare costs associated with arteriovenous fistulas among US hemodialysis patients. Am J Kidney Dis 2018; 72: 10–18.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.